Specific targeting of hypothalamic neurotransmitters, including those involved in circadian rhythms such as orexins [146], have thus far not shown promise in migraine therapeutics, but more focused targeting of individual receptor subtypes, such as neuropeptide Y Y1 agonism (a hypothalamic neuropeptide involved in the regulation of feeding and sleep via interaction with the orexins) may hold potential in the future [147,148]. Here, HCRT is linked to migraine disorder.